Chemistry:25I-NBF

From HandWiki
Short description: Chemical compound
25I-NBF
25i-NBF.svg
Clinical data
ATC code
  • none
Legal status
Legal status
  • BR: F2
  • DE: NpSG (Industrial and scientific use only)
  • UK: Class A
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC17H19FINO2
Molar mass415.247 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

25I-NBF (2C-I-NBF, NBF-2C-I, Cimbi-21) is a derivative of the phenethylamine hallucinogen 2C-I, which acts as a highly potent partial agonist for the human 5-HT2A receptor,[1][2][3] with bias towards the β-arrestin 2 coupled signalling pathway.[4] It has been studied in its 11C radiolabelled form as a potential ligand for mapping the distribution of 5-HT2A receptors in the brain, using positron emission tomography (PET).[5][6]

Legality

25I-NBF is illegal in Hungary,[7] Japan,[8] Latvia,[9] and Vermont.[10]

Sweden

The Riksdag added 25I-NBF to Narcotic Drugs Punishments Act under Swedish schedule I ("substances, plant materials and fungi which normally do not have medical use") as of January 26, 2016, published by Medical Products Agency (MPA) in regulation HSLF-FS 2015:35 listed as 25I-NBF, and 2-(4-jodo-2,5-dimetoxifenyl)-N-(2-fluorobensyl)etanamin.[11]

United Kingdom

This substance is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971.[12]


Analogues and derivatives

References

  1. "Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists". Molecular Pharmacology 70 (6): 1956–1964. December 2006. doi:10.1124/mol.106.028720. PMID 17000863. 
  2. Braden MR (2007). Towards a biophysical understanding of hallucinogen action (Ph.D. thesis). Purdue University. ProQuest 304838368.
  3. "Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists". ACS Chemical Neuroscience 5 (3): 243–249. March 2014. doi:10.1021/cn400216u. PMID 24397362. 
  4. "Identification of psychedelic new psychoactive substances (NPS) showing biased agonism at the 5-HT2AR through simultaneous use of β-arrestin 2 and miniGαq bioassays". Biochemical Pharmacology 182: 114251. December 2020. doi:10.1016/j.bcp.2020.114251. PMID 32998000. https://biblio.ugent.be/publication/8687066. 
  5. Hansen M (2010-12-16). Design and Synthesis of Selective Serotonin Receptor Agonists for Positron Emission Tomography Imaging of the Brain (Ph.D. thesis). University of Copenhagen. doi:10.13140/RG.2.2.33671.14245.
  6. "Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT (2A) agonist PET tracers". European Journal of Nuclear Medicine and Molecular Imaging 38 (4): 681–693. April 2011. doi:10.1007/s00259-010-1686-8. PMID 21174090. 
  7. "A Magyarországon megjelent, a Kábítószer és Kábítószer-függőség Európai Megfigyelő Központjának Korai Jelzőrendszerébe (EMCDDA EWS) 2005 óta bejelentett ellenőrzött anyagok büntetőjogi vonatkozású besorolása" (in Hungarian). https://www.daath.hu/incoming/designer_jogi_lista_20150903_BSZKI_Daath_kieg.pdf. 
  8. "指定薬物名称・構造式一覧(平成27年9月16日現在)" (in Japanese). 厚生労働省. 16 September 2015. https://www.mhlw.go.jp/seisakunitsuite/bunya/kenkou_iryou/iyakuhin/yakubuturanyou/dl/meisho.pdf. 
  9. "Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem" (in Latvian). Ministry of Health of the Republic of Latvia. https://www.vm.gov.lv/images/userfiles/metodiskas_vadlinijas_080914.doc. 
  10. "Regulated Drugs Rule". Vermont Department of Health. https://healthvermont.gov/regs/documents/regulated_drugs_rule_20160101.pdf. 
  11. Ödman, Pär. "Gemensamma författningssamlingen avseende hälso- och sjukvård, socialtjänst, läkemedel, folkhälsa m.m." (in Swedish). Lakemedelsverket. https://lakemedelsverket.se/upload/lvfs/HSLF-FS/HSLFS-FS_2015_35.pdf. 
  12. "The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014" (in en). https://www.legislation.gov.uk/uksi/2014/1106/made.